In an s.c. human ovarian cancer (IGROV1) xenograft grown in a SCID mouse model, animals administered with mouse/human chimeric MOv18 IgE or MOv18 IgG1, intravenously (i.v.)exhibited an initial inhibition of tumour growth up to day 19 post-tumour challenge. Here, IGHE is linked to ovarian cancer.